BioSpace News Archive

Vonco Products LLC, an industry-leader in the manufacture of liquid-tight medical devices, fluid bags and infection prevention solutions announced that it is responding to the nationwide demand for safe and secure COVID-19 testing by increasing production of 95kPa biohazard transport bags.

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that the Company plans to issue its fourth quarter and year-end financial results prior to market opening Monday, February 22, 2021 and management will host an investor audio webcast at 4:30 pm ET to discuss financial results and business highlights

The Company has committed to investing an additional $600,000 to acquire 2 million shares, which brings its total equity position to 8.25 million shares.

Pregna International Ltd - a leading women’s healthcare company – has partnered with Dr. Thomas Burke’s Vayu Global Health Initiative to introduce an economical solution to Post-Partum Haemorrhage – one of the leading causes of maternal mortality.

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended December 31, 2020 (“Q2 FY 2021”).

SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that it has commenced an underwritten public offering of 3,000,000 shares of common stock.

Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to transform outcomes for cancer patients, today announced it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be sold by Oncorus. In addition, Oncorus intends to grant the underwriters a 30-day option to p